Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEANASDAQ:ELUTOTCMKTS:HSTCNASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.81-5.2%$1.92$1.29▼$13.07$68.01M-0.231.13 million shs2.50 million shsELUTElutia$1.81+1.1%$1.94$1.61▼$5.24$74.42M0.8646,431 shs96,932 shsHSTCHST Global$0.30-5.6%$0.73$0.23▼$1.10$17.39M-1.06146 shs580 shsPDSBPDS Biotechnology$1.62+0.6%$1.41$0.85▼$4.42$74.05M1.27495,529 shs898,647 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion0.00%-23.31%+24.83%-36.93%-62.68%ELUTElutia0.00%+1.69%+6.47%-38.01%-44.65%HSTCHST Global0.00%-41.21%-63.73%-63.73%-44.67%PDSBPDS Biotechnology0.00%-7.43%+3.18%+18.25%-40.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEABiomea Fusion2.4714 of 5 stars3.61.00.00.02.62.50.6ELUTElutia3.1535 of 5 stars3.55.00.00.00.63.30.6HSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/APDSBPDS Biotechnology1.3216 of 5 stars3.71.00.00.02.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 3.18Buy$21.401,082.32% UpsideELUTElutia 3.00Buy$8.00341.99% UpsideHSTCHST Global 0.00N/AN/AN/APDSBPDS Biotechnology 3.33Buy$9.00455.56% UpsideCurrent Analyst Ratings BreakdownLatest HSTC, ELUT, PDSB, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/3/2025BMEABiomea FusionPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.006/2/2025BMEABiomea FusionPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/2/2025BMEABiomea FusionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.003/31/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/27/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $13.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/AELUTElutia$24.38M3.05N/AN/A($1.31) per share-1.38HSTCHST GlobalN/AN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$138.43M-$3.55N/AN/AN/AN/A-197.71%-134.84%7/30/2025 (Estimated)ELUTElutia-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%7/28/2025 (Estimated)HSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/APDSBPDS Biotechnology-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)Latest HSTC, ELUT, PDSB, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PDSBPDS Biotechnology-$0.25-$0.21+$0.04-$0.21N/AN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/A3/31/2025Q4 2024BMEABiomea Fusion-$1.00-$0.81+$0.19-$0.81N/AN/A3/27/2025Q4 2024PDSBPDS Biotechnology-$0.29-$0.21+$0.08-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A2.252.25ELUTElutiaN/A0.810.70HSTCHST GlobalN/A0.250.25PDSBPDS Biotechnology0.292.332.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%ELUTElutia74.03%HSTCHST GlobalN/APDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion18.42%ELUTElutia27.60%HSTCHST Global65.82%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5037.57 million30.65 millionOptionableELUTElutia18041.12 million29.77 millionNot OptionableHSTCHST Global157.77 million19.75 millionNot OptionablePDSBPDS Biotechnology2045.71 million41.51 millionOptionableHSTC, ELUT, PDSB, and BMEA HeadlinesRecent News About These CompaniesPDS Biotechnology (NASDAQ:PDSB) Downgraded by Wall Street Zen to "Sell"June 16, 2025 | americanbankingnews.comQ2 EPS Estimate for PDS Biotechnology Decreased by AnalystJune 15, 2025 | americanbankingnews.comPDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street ZenJune 14, 2025 | marketbeat.comPDS Health ranked among most community-minded companiesJune 13, 2025 | beckersdental.comHC Wainwright Expects Reduced Earnings for PDS BiotechnologyJune 13, 2025 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC WainwrightJune 12, 2025 | americanbankingnews.comPDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC WainwrightJune 11, 2025 | marketbeat.comUnpacking the PDS PhenomenonJune 11, 2025 | devdiscourse.comPDS rice will be distributed till June 30: Civil Supplies deptJune 11, 2025 | thehansindia.comPDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCCJune 9, 2025 | globenewswire.comPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society ...June 3, 2025 | morningstar.comPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2025 | globenewswire.comPDS Biotechnology files to sell 9.82M shares of common stock for holdersMay 28, 2025 | msn.comWall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to "Hold"May 26, 2025 | marketbeat.comQ2 EPS Estimates for PDS Biotechnology Increased by B. RileyMay 24, 2025 | marketbeat.comPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of ...May 23, 2025 | uk.finance.yahoo.comPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | globenewswire.comPDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comEarnings call transcript: PDS Biotech’s Q1 2025 results show reduced lossesMay 16, 2025 | uk.investing.comData and sensing technology: Increases the value of PDSMay 16, 2025 | miningreview.comPDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTC, ELUT, PDSB, and BMEA Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.81 -0.10 (-5.24%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.83%) As of 06/20/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Elutia NASDAQ:ELUT$1.81 +0.02 (+1.12%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.55%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.HST Global OTCMKTS:HSTC$0.30 -0.02 (-5.55%) As of 06/20/2025 09:53 AM EasternHST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.PDS Biotechnology NASDAQ:PDSB$1.62 +0.01 (+0.62%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.65 +0.03 (+1.79%) As of 06/20/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
